Suchergebnisse - "Palmieri, Salvatore"

PubPharm (88)

11

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients

enthalten in: European Journal of Haematology | 2022

von Morabito, F. | Zamagni, E. | Conticello, C. | +41

12

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma : Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

enthalten in: Hematological Oncology | 2022

von Bruzzese, A. | Derudas, D. | Galli, M. | +57

13

Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients : italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials

enthalten in: Hematological Oncology | 2022

von Martino, E. | Conticello, C. | Zamagni, E. | +30

14

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma : Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials

enthalten in: Haematologica | 2021

von Gentile, M. | Specchia, G. | Derudas, D. | +53

15

KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life : a retrospective survey in 123 patients

enthalten in: Annals of hematology | 2020

von Palmieri, S. | Rocco, S. | Vitagliano, O. | +17

16

KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients

enthalten in: Annals of hematology | 2020

von Palmieri, S. | Rocco, S. | Vitagliano, O. | +17

17

KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients

enthalten in: Annals of hematology | 2020

von Palmieri, S. | Rocco, S. | Vitagliano, O. | +17

18

KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients

enthalten in: Annals of hematology | 2020

von Palmieri, S. | Rocco, S. | Vitagliano, O. | +17

19

Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis : A pooled analysis

enthalten in: Critical reviews in oncology/hematology | 2018

von Bringhen, S. | Offidani, M. | Palmieri, S. | +26

20

Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients : an Italian multicenter retrospective study

enthalten in: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation | 2014

von Martino, M. | Montanari, M. | Ferrara, F. | +16